Loading
Houston gynaecologic oncologist who led DUO-E, the trial that added durvalumab, with or without olaparib, to first-line chemotherapy for advanced endometrial cancer.
Shannon Westin is a gynaecologic oncologist and clinical trialist at MD Anderson Cancer Center. She was first author of the 2023 Journal of Clinical Oncology report of DUO-E, the phase 3 trial in which durvalumab with carboplatin and paclitaxel, followed by durvalumab with or without olaparib maintenance, improved progression-free survival in newly diagnosed advanced or recurrent endometrial cancer, with the largest benefit in mismatch repair-deficient tumours.
| Title | Journal | Year |
|---|---|---|
| DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer | Journal of Clinical Oncology | 2024 |
Shares Advanced or recurrent endometrial cancer, Endometrial cancer and the tags endometrial, gynaecological, trialist.
Shares Endometrial cancer and the tags endometrial, gynaecological, trialist.
Shares Endometrial cancer and the tags endometrial, gynaecological, trialist.
Shares MD Anderson Cancer Center, Ovarian cancer and the tags gynaecological, trialist.
Shares Endometrial cancer, Ovarian cancer and the tags endometrial, trialist.
Shares Endometrial cancer and the tags endometrial, trialist.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Ovarian cancer.
Shares Ovarian cancer and the tags gynaecological, trialist.